Morphological findings in myelodysplasic syndromes
Hallazgos morfológicos en síndromes mielodisplásicos
Article Sidebar
PDF (Español (España))
FLIP
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Main Article Content
Myelodysplastic Syndromes (MDS) are a group of diverse clonal hematopoietic disorders manifested by morphologic dysplasia in hematopoietic cells and by bone marrow failure, characterized by ineffective hematopoiesis that generates functional alterations, cytopenias, anemia, recurrent infections, and bleeding. It occurs between 65 and 70-year-old patients, especially those who have comorbidities that decrease the therapeutic response. In 2016 the world health organization classified them as MDS with single lineage dysplasia (MDS-SLD), MDS with ring sideroblasts (MDS-RS), MDS with multilineage dysplasia (MDS-MLD), MDS with excess blasts (MDS-EB) type 1 (MDS-EB-1), and type 2 (MDS-EB-2), MDS with isolated del(5q), MDS unclassifiable (MDS-U), and Refractory cytopenia of childhood (RCC). The diagnosis can be assessed by different methodologies; such as immunophenotype by flow cytometry, cytogenetics, and morphological observation of dysplasia in peripheral blood and bone marrow, which reveal the type of myelodysplasia and the prognosis of the patient. Dysplasia can occur in one or more cell lines, being the most relevant the changes in the nuclei, such as karyorrhexis, internuclear bridging in the erythroid lineage; also abnormal chromatin changes in granulocytes (lobulation, shape, and number alterations), small size, and megaloblastic changes; and in the cytoplasm the presence of iron deposits such as ringed sideroblasts, hypogranulation, aberrant Chediak-type granules, toxic or mixed granulations, and presence of micromegakaryocytes. The morphological changes in the peripheral blood are the first approach to diagnose dysplasia, which is why it is necessary to strengthen the observation of peripheral blood and bone marrow smears in 100X, associated with cell counts, to ensure a timely diagnosis of the Myelodysplastic Syndrome.
Downloads
Article Details
Prates D, Basquiera A, Belli C, Canónico V, Fazio P, González J, et al. Síndromes mielodisplásicos. Sociedad Argentina de hematología: Guía de diagnóstico y tratamiento. [Internet]. 2010;(14):397-398. Disponible en: http://sah.org.ar/docs/395-416.9.SAH_GUIA2012_GuiasSAH_SMD-Aindd.pdf.
Cazzola M, Della Porta MG, Travaglino E, Malcovati L. Classification and prognostic evaluation of Myelodysplastic syndromes. Semin Oncol [Internet]. 2011;38(5):627–34. Disponible en https://doi.org/10.1053/j.seminoncol.2011.04.007
Malcovati L, Cazzola M. Myelodysplastic/myeloproliferative disorders. Haematologica. [Internet]. 2008;93:4-6. Disponible en https://10.3324/haematol.11374
Reiter A, Invernizzi R, Cross NC, Cazzola M. Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica. [Internet]. 2009;94:1634-8. Disponible en https://doi.org/10.3324/haematol.2009.014001.
Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. [Internet]. 2010;28(17):47-52. Disponible en https://doi.org/10.1200/JCO.2009.25.2395.
Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. [Internet]. 2016;91(1):76–89. Disponible en https://doi.org/10.1002/ajh.24253.
Nucifora E, Zimerman J, Fazio P, Prates MV. Diagnòstico de Sindromes mielodisplàsicos (SMD). Hematología. [Internet]. 2010;14(3):103-107. Disponible en http://www.sah.org.ar/revista/numeros/vol14.n3.103-107.pdf
López F, Diez M. Síndromes mielodisplásicos. Rev La Educ Super. Medicine. [Internet]. 2016;12(21):1224-1234. Disponible en https://doi.org/10.1016/j.med.2016.10.013.
Rodríguez JH, Acosta I. Actualización en Síndromes Mielodisplásicos (SMD). Cátedra de hematología. Facultad de Ciencias Bioquímicas y Farmacéuticas. Universidad Nacional del Rosario. Rev Med Rosario. [Internet]. 2011(77):24-41. Disponible en: http://www.circulomedicorosario.org/Upload/Directos/Revista/0a99e3Rodriguez.pdf
Gorczyca W. Atlas of Differential Diagnosis in Neoplastic Hematopathology. Myelodysplastic Syndromes. Tercera edición. Estados Unidos. Taylor & Francis Group. [Internet]. 2014:565-569. Disponible en https://doi.org/10.1201/b16685
Serdlow SH, Campo E, Harris NL, Et al. Sindromes mielodisplásicos. World Health Organization Classification of Tumours Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer, Lyon, France, 2017:97-120.
Lourdes F, Arenillas L, Senent L, Vallespi T, Álvarez S, Ballesteros M., et al. Guías españolas de diagnóstico y tratamiento de los SMD y la LMMC. Grupo acción médica. Madrid. [Internet]. 2012;97(5):6-10. Disponible en: https://www.gesmd.es/wp-content/uploads/2013/10/Diag-y-Tratamiento-SMD-y-LMMC-noprint.pdf.
Carnot J. Sindromes mielodisplásicos, diagnóstico, estudio y tratamiento. Manual de Prácticas Médicas- Hospital Hermanos Ameijeiras. (s.f.): 1-28. Disponible en: http://www.sld.cu/galerias/pdf/sitios/hematologia/smdarreglado.pdf
Prates V, Nuciflora E, Alfonso G, Narbaitz M, Gómez M, López I, et al., Guía diagnóstica y terapéutica, Guía Argentina de Hematología. [Internet]. 2010;(1); 3-36. Disponible en http://www.sah.org.ar/guias_hematolo.asp.
Itzykson R, Roudot H, Fenaux P. Myelodysplastic syndromes and myelodysplastic / myeloproliferative neoplasms. Diagnostic Techniques in Hematological Malignancies. United States of America by Cambridge University Press, New York. [Internet]. 2010:306-318. Disponible en https://doi.org/10.1017/CBO9780511760273.016
Kalina T, Flores M J, Van Der Velden VHJ, Ayuso M, Böttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. [Internet]. 2012;26(9):1986–2010. Disponible en: https://www.nature.com/articles/leu2012122
Montalban G. Garcia G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Wiley AJH. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas. [Internet]. 2018(93):129-147. Disponible en https://doi.org/10.1002/ajh.24930
Van Dongen JJM, Lhermitte L, Böttcher S, Almeida J, Van Der Velden VHJ, Flores M. J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. [Internet]. 2012;26(9):1908-75. Disponible en: https://www.nature.com/articles/leu2012120
Varela H, Patussi R, Cameirao L, Costa A, Arandas F, Marega A, Et al. Myelodysplastic syndrome: validation of flow cytometry multilineage score system. Einstein Sao Paulo. [Internet]. 2020(18);1-6. Disponible en https://doi.org/10.31744/einstein_journal/2020AO4966
Duetz C, Westers T, Van de Loosdrecht. Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes. Pathobiology. Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. [Internet]. 2019;(86):14-23. Disponible en https://doi.org/10.1159/000490727
Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME: Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. [Internet]. 2001;98:979. Disponible en https://doi.org/10.1182/blood.v98.4.979
Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, et al. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica. [Internet]. 2017;102:308-319. Disponible en: https://doi.org/10.3324/haematol.2016.147835
Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. [Internet]. 2008;87(7):515-26. Disponible en https://doi.org/10.1007/s00277-008-0483-y
Borjas C, Domínguez M, Gonzales JR. La citogenética de los síndromes mielodisplásicos y su impacto como factor pronóstico. Revista Médica del Instituto Mexicano del Seguro Social. [Internet]. 2017;55(4):481-489. Disponible en: https://www.medigraphic.com/pdfs/imss/im-2017/im174l.pdf
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. [Internet]. 1997;89(6):2079-88. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9058730/
Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodisplastic syndromes. J Clin Oncol. [Internet]. 2007;25(23):3503-10. Disponible en https://doi.org/10.1200/JCO.2006.08.5696
Zini G. Diagnostics and Prognostication of Myelodysplastic Syndromes. Ann La Med. [Internet]. 2017(37):465-474. Disponible en https://doi.org/10.3343/alm.2017.37.6.465
Flores M, Alfonso G, Basquiera J, Cismondi AL, de Dios Soler M, Enrico A, et al. Síndromes mielodisplásicos y síndromes de superposición mielodisplasia/neoplasia mieloproliferativa. Soc Argentina Hematol Guía Diagnostico y Trat [Internet]. 2017;611-38. Disponible en: http://sah.org.ar/docs/2017/011-SMD.pdf
Montalvan G, Garcia G. Myelodysplastic Syndromes: 2018 Update on Diagnosis, Risk-Stratification and Management. Am J Hematol. [Internet]. 2018;93(1).129-147. Disponible en https://doi.org/10.1002/ajh.24930
Lefévre C, Bondu S, Le Golff S, Kosmider S, Fontenay M. Dyserythropoiesis of myelodysplastic syndromes. Wolters Kluwer. [Internet]. 2017;24(3):191-197. Disponible en https://doi.org/10.1097/MOH.0000000000000325
Iwama A. Diseritropoyesis en el síndrome mielodisplásico. Rinsho Ketsueki. Pubmed. [Internet]. 2018;59(10):2036-2041. Disponible en https://doi.org/10.11406/rinketsu.59.2036
Boveri E, Croci G, Gianelli U, Gambacorta M, Isimbaldi G, Alessia M, Et al. Histopathological and inmunohistochemical evaluation of bone marrow biopsy in mielodysplastic síndromes. Int. J. Hematol. Oncol. [Internet]. 2013;2(3):219-228. Disponible en https://doi.org/10.2217/ijh.13.22
Porta Della M, Travaglino E, Boven E, Ponzoni M, Malcovati L, Papaemmanuil E. Et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Nature. Macmillan Publishers Limited. [Internet]. 2015;(29):66-75. Disponible en https://doi.org/10.1038/leu.2014.161
Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res [Internet]. 2020;36(6):727-34. Disponible en https://doi.org/10.1016/j.leukres.2012.02.014
Liang C, Li J, Cheng J, Chen S, Ye Z, Zhang F, et al. Characteristics of bone marrow cell dysplasia and its effectiveness in diagnosing myelodysplastic syndrome. Hematology. [Internet]. 2018;23(2):65-76. Disponible en https://doi.org/10.1080/10245332.2017.1347247
Rodríguez JH, Lujan I, Cátedra. Actualización en Síndrome mielodisplasico (SMD). Rev Med Rosario. [Internet]. 2011;(77):24-41. Disponible en: http://www.circulomedicorosario.org/Upload/Directos/Revista/0a99e3Rodriguez.pdf
Jean E, Bennett JM, Bain B, Brunning R, Vallespi MT, Tomonaga M. Et al. Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas. British Journal of Hematology. [Internet]. 2018;(23):526-533. Disponible en https://doi.org/10.1111/bjh.15435
Wenchee S, Philippa C, Haji R, Gabriel I, Bain B. Striking dyserythropoiesis in a myelodysplastic syndrome. Am J Hematol. [Internet]. 2017;92(2):218. Disponible en https://doi.org/10.1002/ajh.24549
Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. [Internet]. 2016;91(1):76–89. Disponible en https://doi.org/10.1002/ajh.24253
Mazzone A, Porta C, Gianluca F, Gritti D, Mazzuccheli I, Ricevuti G. Granulocyte Dysplasia and Dysfunction, and CD11/CD18 Defects in Myelodysplastics Syndromes. Leukemia and Lymphoma. [Internet]. 2012;23 (3-4):267-275. Disponible en https://doi.org/10.3109/10428199609054829
Goasguen JE, Bennett JM, Bain BJ, Brunning R, Vallespi MT, Tomonaga M, et al. Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. [Internet]. 2014;38(4):447–53. Disponible en https://doi.org/10.1016/j.leukres.2013.12.020.
Jaramillo P. Junio 2019. Técnica digital. Archivo de la autora.
